Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
09 Mar 2019
Historique:
received: 05 07 2018
revised: 09 01 2019
accepted: 25 01 2019
entrez: 13 3 2019
pubmed: 13 3 2019
medline: 2 5 2019
Statut: ppublish

Résumé

Stent retriever thrombectomy of large-vessel occlusion results in better outcomes than medical therapy alone. Alternative thrombectomy strategies, particularly a direct aspiration as first pass technique, while promising, have not been rigorously assessed for clinical efficacy in randomised trials. We designed COMPASS to assess whether patients treated with aspiration as first pass have non-inferior functional outcomes to those treated with a stent retriever as first line. We did a multicentre, randomised, open label, blinded outcome, core lab adjudicated non-inferiority trial at 15 sites (ten hospitals and four specialty clinics in the USA and one hospital in Canada). Eligible participants were patients presenting with acute ischaemic stroke from anterior circulation large-vessel occlusion within 6 h of onset and an Alberta Stroke Program Early CT Score of greater than 6. We randomly assigned participants (1:1) via a central web-based system without stratification to either direct aspiration first pass or stent retriever first line thrombectomy. Those assessing primary outcomes via clinical examinations were masked to group assignment as they were not involved in the procedures. Physicians were allowed to use adjunctive technology as was consistent with their standard of care. The null hypothesis for this study was that patients treated with aspiration as first pass achieve inferior outcomes compared with those treated with a stent retriever first line approach. The primary outcome was non-inferiority of clinical functional outcome at 90 days as measured by the percentage of patients achieving a modified Rankin Scale score of 0-2, analysed by intent to treat; non-inferiority was established with a margin of 0·15. All randomly assigned patients were included in the safety analyses. This trial is registered at ClinicalTrials.gov, number: NCT02466893. Between June 1, 2015, and July 5, 2017, we assigned 270 patients to treatment: 134 to aspiration first pass and 136 to stent retriever first line. A modified Rankin score of 0-2 at 90 days was achieved by 69 patients (52%; 95% CI 43·8-60·3) in the aspiration group and 67 patients (50%; 41·6-57·4) in the stent retriever group, showing that aspiration as first pass was non-inferior to stent retriever first line (p A direct aspiration as first pass thrombectomy conferred non-inferior functional outcome at 90 days compared with stent retriever first line thrombectomy. This study supports the use of direct aspiration as an alternative to stent retriever as first-line therapy for stroke thrombectomy. Penumbra.

Sections du résumé

BACKGROUND BACKGROUND
Stent retriever thrombectomy of large-vessel occlusion results in better outcomes than medical therapy alone. Alternative thrombectomy strategies, particularly a direct aspiration as first pass technique, while promising, have not been rigorously assessed for clinical efficacy in randomised trials. We designed COMPASS to assess whether patients treated with aspiration as first pass have non-inferior functional outcomes to those treated with a stent retriever as first line.
METHODS METHODS
We did a multicentre, randomised, open label, blinded outcome, core lab adjudicated non-inferiority trial at 15 sites (ten hospitals and four specialty clinics in the USA and one hospital in Canada). Eligible participants were patients presenting with acute ischaemic stroke from anterior circulation large-vessel occlusion within 6 h of onset and an Alberta Stroke Program Early CT Score of greater than 6. We randomly assigned participants (1:1) via a central web-based system without stratification to either direct aspiration first pass or stent retriever first line thrombectomy. Those assessing primary outcomes via clinical examinations were masked to group assignment as they were not involved in the procedures. Physicians were allowed to use adjunctive technology as was consistent with their standard of care. The null hypothesis for this study was that patients treated with aspiration as first pass achieve inferior outcomes compared with those treated with a stent retriever first line approach. The primary outcome was non-inferiority of clinical functional outcome at 90 days as measured by the percentage of patients achieving a modified Rankin Scale score of 0-2, analysed by intent to treat; non-inferiority was established with a margin of 0·15. All randomly assigned patients were included in the safety analyses. This trial is registered at ClinicalTrials.gov, number: NCT02466893.
FINDINGS RESULTS
Between June 1, 2015, and July 5, 2017, we assigned 270 patients to treatment: 134 to aspiration first pass and 136 to stent retriever first line. A modified Rankin score of 0-2 at 90 days was achieved by 69 patients (52%; 95% CI 43·8-60·3) in the aspiration group and 67 patients (50%; 41·6-57·4) in the stent retriever group, showing that aspiration as first pass was non-inferior to stent retriever first line (p
INTERPRETATION CONCLUSIONS
A direct aspiration as first pass thrombectomy conferred non-inferior functional outcome at 90 days compared with stent retriever first line thrombectomy. This study supports the use of direct aspiration as an alternative to stent retriever as first-line therapy for stroke thrombectomy.
FUNDING BACKGROUND
Penumbra.

Identifiants

pubmed: 30860055
pii: S0140-6736(19)30297-1
doi: 10.1016/S0140-6736(19)30297-1
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02466893']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

998-1008

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Aquilla S Turk (AS)

Department of Neurosurgery, Greenville Health System, Greenville, SC, USA. Electronic address: aturk@ghs.org.

Adnan Siddiqui (A)

Department of Neurosurgery, University at Buffalo, Buffalo, NY, USA.

Johanna T Fifi (JT)

Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Reade A De Leacy (RA)

Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

David J Fiorella (DJ)

Cerebrovascular Center, Stony Brook University, Stony Brook, NY, USA.

Eugene Gu (E)

Cerebrovascular Center, Stony Brook University, Stony Brook, NY, USA.

Elad I Levy (EI)

Department of Neurosurgery, University at Buffalo, Buffalo, NY, USA.

Kenneth V Snyder (KV)

Department of Neurosurgery, University at Buffalo, Buffalo, NY, USA.

Ricardo A Hanel (RA)

Lyerly Neurosurgery, Baptist Medical Center, Jacksonville, FL, USA.

Amin Aghaebrahim (A)

Lyerly Neurosurgery, Baptist Medical Center, Jacksonville, FL, USA.

B Keith Woodward (BK)

Department of Radiology, Fort Sanders Regional Medical Center, Knoxville, TN, USA.

Harry R Hixson (HR)

Department of Radiology, Fort Sanders Regional Medical Center, Knoxville, TN, USA.

Mohammad I Chaudry (MI)

Department of Neurosurgery, Greenville Health System, Greenville, SC, USA.

Alejandro M Spiotta (AM)

Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, USA.

Ansaar T Rai (AT)

Department of Neurointerventional Radiology, West Virginia University, Morgantown, WV, USA.

Donald Frei (D)

Radiology Imaging Associates/RIA Neurovascular, Swedish Medical Center, Englewood, CO, USA.

Josser E Delgado Almandoz (JED)

Department of Radiology, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Mike Kelly (M)

Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada.

Adam Arthur (A)

Department of Neurosurgery, Semmes Murphey Clinic, Memphis, TN, USA.

Blaise Baxter (B)

University of Tennessee Health Sciences Center, Memphis, TN, USA; Department of Radiology, Erlanger Medical Center, Chatanooga, TN, USA.

Joey English (J)

Department of Neurointerventional Services, California Pacific Medical Center, San Francisco, CA, USA.

Italo Linfante (I)

Cardiac and Vascular Institute, Miami Vascular Specialist, Miami, FL, USA.

Kyle M Fargen (KM)

Department of Neurosurgery, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.

J Mocco (J)

Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH